Evolution of the Average Target: Summit Therapeutics Inc.

Evolution of the Average Target - Summit Therapeutics Inc.

Evolution of the Target Price: Summit Therapeutics Inc.

Evolution of the Target Price - Summit Therapeutics Inc.

Changes in Analyst Recommendations: Summit Therapeutics Inc.

acd7a45b09d640def508b4d7df.-SQ6NYX__uYS4bCbWf5cUeQijHE7pA7FtBZiCCOVs_E.ihVpYvKqjtJaleffOrRlJYJS5gNKxWKhh3ExX23Y4pq_V3lAz63HkEeT4Q~c91aebd13ce839ba3ceca55b4c14be5a
09-29 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
09-29 Stocks Defy the Pressure Zonebourse
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
07-24 Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept MT
06-22 Analyst recommendations: Accenture, Conocophillips, Diamondback Energy, Oracle, Applied Materials… Zonebourse
05-27 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
05-22 Summit Therapeutics Shares Fall After HC Wainwright Downgrade MT
05-22 Bernstein Initiates Summit Therapeutics at Underperform MT
05-22 HC Wainwright Downgrades Summit Therapeutics to Neutral From Buy MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
12-17 Barclays Upgrades Summit Therapeutics to Equal Weight From Underweight, Adjusts Price Target to $18 From $16 MT
21/10/25 Analyst recommendations: Apple, Rivian, Goldman Sachs, Lyft, Morgan Stanley… Zonebourse
20/10/25 Summit Therapeutics Inc. Plans to Submit a BLA in Fourth Quarter 2025 for Ivonescimab Based on Harmoni Global Phase III Study Results CI
17/09/25 Barclays Initiates Summit Therapeutics at Underweight With $13 Price Target MT
04/09/25 Guggenheim Initiates Summit Therapeutics at Buy With $40 Price Target MT
19/08/25 Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target MT
13/08/25 Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says MT
01/07/25 UBS Initiates Summit Therapeutics at Buy With $30 Price Target MT
11/06/25 Leerink Partners Initiates Coverage on Summit Therapeutics With Underperform Rating, $12 Price Target MT
08/05/25 TD Cowen Initiates Summit Therapeutics at Buy MT
25/04/25 Top Midday Decliners MT
26/03/25 Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+108.09%
+34.22%
+28.94%
+9.74%
+10.62%
+17.69%
+40.75%
+41.74%
+30.99%
+4.58%
Average +32.74%
Weighted average by Cap. +26.97%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
10.86GBP
Average target price
22.58GBP
Spread / Average Target
+107.85%
High Price Target
32.70GBP
Spread / Highest target
+201.06%
Low Price Target
8.896GBP
Spread / Lowest Target
-18.09%

Analyst Consensus Detail

Analyst consensus - Summit Therapeutics Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Summit Therapeutics Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock
  4. Consensus Summit Therapeutics Inc.